Which inhaler combines albuterol (salbutamol) and budesonide?

Airsupra (Albuterol-Budesonide) is the Combination Inhaler

The FDA-approved inhaler containing both albuterol and budesonide is marketed as Airsupra (albuterol 90 μg/budesonide 80 μg per actuation), approved in 2023 for as-needed use in adults ≥18 years with asthma. This represents a paradigm shift in asthma management, combining a short-acting beta-2 agonist (SABA) with an inhaled corticosteroid (ICS) in a single pressurized metered-dose inhaler (pMDI) 1, 2.

Key Clinical Details

Dosing and Administration:

• Each dose consists of two actuations (total 180 μg albuterol/160 μg budesonide per dose)
• Used as-needed for symptom relief or prevention of bronchoconstriction
• Can be used with or without maintenance ICS therapy
• Not indicated for maintenance therapy or single maintenance and reliever therapy (SMART) 2

Evidence Supporting Use

The approval was based primarily on the MANDALA trial 3, 4, which demonstrated:

• 47% reduction in severe asthma exacerbations compared to albuterol alone (rate ratio 0.53,95% CI 0.39-0.73) 1
• Reduced systemic corticosteroid burden (23.2 vs 61.9 mg per year) 1
• Similar safety profile to albuterol monotherapy despite regular use 4

The more recent BATURA trial 1 extended these findings to mild asthma, showing:

• 46% lower risk of severe exacerbations in patients with uncontrolled mild asthma (hazard ratio 0.54,95% CI 0.40-0.73)
• Benefit even in patients using only SABA at baseline (74.4% of participants)

Important Clinical Considerations

Appropriate Patient Selection:

• FDA-approved for adults ≥18 years (pediatric data limited) 2
• Most beneficial for patients with episodic symptoms requiring frequent rescue therapy
• May not be optimal for patients with very low or very high symptom perception 5

Pattern of Use:

• In clinical trials, mean use was 2.6-2.8 inhalations/day 4
• High daily use (≥8 inhalations/day) was rare
• Patients maintained adherence to background maintenance therapy on ≥75% of days 4

Safety Profile:

• No increase in ICS-related adverse events compared to albuterol alone 1, 4
• Well-tolerated even with regular, relatively high daily doses over 12 weeks 6
• Similar bronchodilation onset and duration to albuterol monotherapy 6

Alternative Formulations

For nebulizer use only (not a single-device combination):

• Albuterol and budesonide inhalation suspensions can be mixed in the same nebulizer for concurrent administration 7
• This is explicitly noted as compatible in NAEPP guidelines 7
• Levalbuterol is also compatible with budesonide suspension 7

Clinical Pitfalls to Avoid

1. Do not confuse with maintenance combination inhalers (formoterol-budesonide or salmeterol-fluticasone) - Airsupra is rescue therapy only
2. Do not use ultrasonic nebulizers for budesonide suspensions - only jet nebulizers are effective 7
3. Counsel patients on proper technique - requires two actuations per dose for full effect
4. Monitor for overuse - increasing rescue use signals poor asthma control requiring step-up in maintenance therapy

The combination addresses both bronchoconstriction and inflammation during the critical "window of opportunity" when asthma control is lost, representing a mechanistic advantage over SABA-only rescue therapy 2.